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ABSTRACT: A series of platinum based low molecular weight urea-based gelators C1, C2 and C3, mimicking the structure of the 
anticancer drug cisplatin has been synthesized, as part of the development of a targeted, supramolecular gel phase crystallization 
and polymorphism screening strategy. Morphological and rheological studies established that inclusion of a longer spacer between 
the urea and cisplatin-mimetic regions of the gelator (C3) resulted in optimal gelation performance. Interfacial crystallization of 
cisplatin in a gel-sol biphasic system has been employed to address the insolubility of the drug molecule in organic solvents. A new 
N,N-dimethylacetamide (DMA) solvate of cisplatin has been identified and a crystal habit modification of the known N,N-
dimethylformamide (DMF) solvate form of cisplatin has been observed on crystallization of cisplatin in C3 gels prepared in xy-
lenes. While both targeted and non-targeted gels resulted in the formation of the new DMA solvate, only the targeted C3 gel result-
ed in high quality single crystal suitable for characterization by single crystal crystallography. The high crystal quality is attributed 
to a close match between the core geometry of C3 with that of cisplatin together with local order in the gel fibers of C3. 
INTRODUCTION 
Polymorphism and the methods used to discover drug solid 
forms are key issues in the pharmaceutical industry, drawing 
huge intellectual and financial investment.
1
 Different crystal 
forms (polymorphs, pseudopolymorphs, salts or cocrystals) 
have different bioavailability and solubility, while  crystal 
morphology significantly affects processing and tableting be-
haviour.
1,2, 3
 The pharmaceutical industry has adopted exten-
sive solid form screening protocols in order to ensure the iden-
tification of all polymorphic and solvate forms of new drug 
entities. However, the case of ritonavir illustrates that the nu-
cleation of even the most stable polymorphic modification can 
be difficult, particularly if the conformation in the crystal is 
different to the form in solution.
4 
While the use of a metastable 
or solvate crystal in a pharmaceutical dosage form can some-
times be justified because a medical benefit is achieved,
5
 it is 
vital from a regulatory standpoint that a thorough characteriza-
tion of the solid state chemistry of a new drug substance is 
achieved and all possible forms are identified.
6 
In addition to 
polymorphic form, the external morphology of a crystalline 
material can be important, with a number of examples demon-
strate the effects of changing morphology on in vitro dissolu-
tion rate, with potential for improving the bioavailability.
7 
Thus, there remains a demand for novel, modern polymorph 
screening technologies which can extend the solid form nucle-
ation and growth parameter space, particularly for hard-to-
nucleate solid forms.  
As an alternative to solution-based methods, growing crystals 
from aqueous silica gel or aqueous biogels is a well-
established technique.
8
 Very recently, an approach based on 
self-assembled fibers of low molecular weight gelators
9
 
(LMWGs)
 
has emerged as a chemically diverse, reversible and 
synthetically tuneable alternative to traditional gel media.
10
 
However, the potential of supramolecular gels as a medium for 
crystal growth remains largely unexplored,
11
 with the excep-
tion of some interesting work on inorganic crystal growth as 
part of studies on biomineralisation.
12
 In 2010 our group 
demonstrated for the first time that the crystals of several 
model pharmaceutical compounds can be grown in supramo-
lecular gels in a variety of solvents.
13
 However, the gelators 
used in this study were generic in nature and lacked specific 
interaction with the drug molecules. A more fine-tuned ap-
proach would involve chemically targeting the structure of the 
gelator in terms of molecular geometry and functional groups 
to match that of the drug substance hence offering the possibil-
ity of a lowered nucleation barrier or even epitaxial over-
growth of the drug substance on the locally ordered gel fibers.  
The role of a gel in a crystallization process is slowing down 
the diffusion of substrates, eliminating convection and provid-
ing homogeneous medium for nucleation free of active surfac-
es such as glass or dust.
11,14  
A classical gel phase crystalliza-
tion therefore involves very slow diffusion of two reactants 
together in a gel to produce an insoluble product that deposits 
in the gel medium. However, the local one-dimensional order-
ing of  gel fibers potentially offers an active, surface on which 
substrate nucleation can occur in such a way that the periodici-
ty of the gel fiber underlies, and is transferred to the growing 
crystal in a process of heterogeneous secondary nucleation.   
  
2 
 
Scheme 1: Preparation of cisplatin-mimetic gelators 
This kind of growth of a daughter phase on a parent substrate 
was responsible, for example, for the recent isolation of a 
computationally predicted catameric carbamazepine form V 
by growth on a dihydrocarbamazepine (DHC) form II parent 
phase..
15
 Herein, we report for the first time, the use of a drug-
mimetic LMWG as a template for the growth of a specific 
drug, namely cisplatin, an important and clinically approved 
chemotherapeutic drug used for the treatment of testicular and 
ovarian cancers.
16 
  
Cisplatin is structurally simple and its polymorphism is well-
established; it represents a case where there is considerable 
confidence that no hitherto undiscovered forms exist. The first 
published crystal structure of cisplatin was the low resolution 
determination of the alpha form reported five decades ago,
17
 
while the beta form was reported in the patent literature.
18
 
Only recently, has detailed structural information for these two 
pure forms has been reported with the help of single crystal X-
ray and neutron powder diffraction experiments.
19
 There are 
also two known polymorphs of a solvate form of cisplatin 
containing N,N-dimethylformamide (DMF),
20
 a DMF solvated 
complex with [18]crown-6,
21
 and a remarkable metallocage 
cisplatin inclusion compound.
22
 The presence of only a limited 
number of functional groups (which makes the molecule in-
soluble in most organic solvents), together with the presence 
of the relatively labile chloro ligands (which undergo ex-
change with water as part of the drug’s mode of action) leaves 
only limited scope for further polymorphism and hence offers 
a challenging test case for novel solid form screening method-
ologies. 
 In the present work we have prepared a series of cispla-
tin-mimetic metal complexes C1, C2 and C3, involving a cis-
dichloro platinum(II) linker bound to the respective pyridine-
based ligands L1, L2 and L3 (Scheme 1). These metal-bridged 
bis(urea) metallogelators have the potential to form gels based 
on the self-assembly of the urea functional groups,
23,24
 while 
the dodecyl chains enhance the solubility in organic solvents, 
and at the same time participate in strong van der Waals inter-
actions, facilitating the formation of fibrous networks. With 
the exception of one earlier report of a silver(I) coordinated 
mono urea based gel system,
25
 the use of a metal center to link 
two urea-based ligands to give a gel-forming bis(urea) motif 
by metal complexation has not been reported. It represents a 
simple and highly versatile approach to the preparation of a 
range of bis(urea)s as well as incorporating inter alia the target 
cisplatin-mimetic functionality. The variability of the pyridyl-
urea spacer group offers the scope to investigate the effect of 
relative distance between the coordinating segment and self-
assembling segment on the overall gelation and templating 
behavior of the system. 
 The novelty of this work lies in three key elements: first-
ly, the concept of linking two monoureas together using a 
metal-ligand strategy facilitating the gel formation and sec-
ondly, the design of a specific drug-mimetic gel as an example 
of an advanced pharmaceutical crystallization strategy for 
solid form discovery. Thirdly, the work also reports a new gel-
sol interfacial crystallization technique to address the different 
solubilities of the drug and gelator. 
 
RESULTS AND DISCUSSION 
Synthesis of Cisplatin-Mimetic Gelators. Gelators  C1, C2 
and C3 were prepared from the reaction of respective ligands 
L1, L2 and L3 with potassium tetrachloroplatinate(II) in a 2-
propanol/water mixture at 75 
o
C for 3 days. Final purification 
was carried out by column chromatography. Gelators were 
characterized by 
1
H, 
13
C, 
195
Pt NMR spectroscopy and spectra 
were assigned with the aid of 
1
H-
1
H gCOSY, 
1
H-
13
C gHSQC, 
1
H-
13
C gHMBC, 
1
H-
15
N gHMBC in DMF-d7 solution at 298 
K. Table 1 summarizes key chemical shifts changes on coor-
dination. The pyridine nitrogen atom N1 was identified unam-
biguously as the coordination site by 
1
H-
15
N gHMBC, where a 
large chemical shift change for N1 was observed for all the 
complexes compared to only a negligible chemical shift 
change for N7 and N9 associated with the urea moiety 
(Scheme 1).  As expected, the hydrogen atoms adjacent to N1 
experienced significant downfield shifts upon complexation. 
The hydrogen atom attached to N7 in C1 also experiences a 
large downfield shift reflecting its proximity to the coordina-
tion site. 
 The 
195
Pt NMR resonances for all three complexes lie in 
the same range implying a similar environment for the Pt(II) 
centers in each case. The 
195
Pt NMR signals for complexes of 
this type vary significantly depending on the ligand type, ge-
ometry (cis-/trans-) and the solvent.
26 
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Table 1. 
1
H, 
13
C, 
15
N differential chemical shifts (Complex - Ligand, in ppm) upon complexation and 
195
Pt chemical shifts (in 
ppm) as observed for the complexes (‘w’ represents a weak signal) 
Complex  1H NMR  13C NMR  1H-15N gHMBC  195Pt 
  C2H C3H N7H N9H  C2 C3  N1 N7 N9   
C1  0.36 0.17 0.39 0.18  2.53 2.83  138.4 1.40 1.50  -1962.53 
-1941.79 (w) 
C2  0.28 0.3 0.17 0.14  3.37 3.79  132.33 -1.49 0.38  -1960.64 
C3  0.29 0.29 0.12 0.01  3.22 3.87  132.18 -0.77 -0.01  -1960.36 
Table 2. Raman frequencies for complexes C1 – C3 (663 
nm laser, ‘sh’ indicates a shoulder) 
 
Generally, pyridyl complexes resonate at lower field than their 
amine analogues because of the weaker basicity of the pyri-
dine ligand. The appearance of single signal in the 
195
Pt NMR 
spectra of C2 and C3 implies a single isomeric form of the 
complexes. For C1 a second weak signal was observed indi-
cating the possible presence of a small amount of the trans 
isomer. The cis isomeric form is a crucial aspect of the gelator 
design. As chloride has a greater trans effect than pyridyl lig-
ands, the synthetic route is expected to favor the cis geome-
try.
27
 However the difference between chloride and pyridyl 
ligands is relatively small in terms of trans effect, and hence 
we examined the complexes by Raman spectroscopy to con-
firm isomeric form. The cis form of the complexes has C2v 
symmetry and thus both symmetric and antisymmetric Pt-Cl 
stretching vibrations are Raman active. The trans isomers are 
D2h and only the symmetric Pt-Cl stretching is Raman active. 
As summarized in Table 2, C2 and C3 clearly showed two 
bands, while a peak with a shoulder was observed for C1. 
These results confirm a cis geometry for C2 and C3, and sug-
gest a small fraction of trans form in case of C1. 
 
Preparation and Characterization of the Gel Samples. The 
gelation behaviors of C1, C2 and C3 were tested in a variety 
of organic solvents by dissolving the solid samples at a high 
temperature followed by cooling to room temperature. Gela-
tion was evaluated by the simple ‘stable to inversion’ test. C1 
and C3 behaved similarly and form gels in xylenes (o-, m- and 
p-), toluene and chloroform. On the other hand, C2 formed 
gels in a series of alcohols (Supporting Information Table S1).  
 The morphologies of the xerogel samples vary from fi-
bril-like to ribbon-like to well-defined fibrils for C1, C2 and 
C3, respectively, as studied by scanning electron microscopy 
(SEM) (Figure 1 and Supporting Information Figure S22). 
This variation is also reflected in rheology of the samples. 
While C2 exhibited the highest value of the storage modulus 
at 2.5% w/v, gels of C3 showed the highest yield stress (Fig-
ure 2). 
 Formation of the assembled fibers driven by intermolec-
ular hydrogen bonding of the bis(urea) moieties is evidenced 
by the temperature dependent NMR spectra of complexes C1 
and C3 in deuterated chloroform, a gel-forming solvent (Sup-
porting Information Figure S23-S24).
28
 The urea hydrogen 
atoms (attached to N7 and N9) in C3 exhibited a marked up-
field shift in at higher temperature even at high dilution, which 
is characteristic of hydrogen bond based assembly.
29 
Interest-
ingly, the hydrogen atoms attached to the urea group N7 and 
N9 in C1 responded differently to the temperature change. 
While the latter shifted up-field, the former showed the oppo-
site behavior with increasing temperatures. This behavior is 
attributed to the conformational rigidity associated with the 
direct attachment of the urea moiety to the coordinating site, 
preventing optimum hydrogen bonding interactions. The van 
der Waals interactions among the dodecyl chains are also ex-
pected to play an important role in forming the network struc-
ture. Other possible modes of intermolecular interaction in-
clude Pt-Pt interaction and π-π interaction via the pyridyl 
rings. The presence of alkylene spacers in the complexes plays 
a crucial role in isolating the coordination region and self-
assembling region. The square planar geometry of the coordi-
nated platinum center should impose some degree of confor-
mational restriction to the rest of the molecule in achieving a 
suitable alignment for constructing a one-dimensional assem-
bly. This restriction is most significant in the case of C1 be-
cause of the closest proximity of the coordination and gelation 
domains. Additionally, direct attachment of the urea moiety to 
the aromatic ring substantially diminishes the efficiency of 
hydrogen bond formation in C1. On the other hand, the two 
domains are apparently isolated in C3, giving rise to the high-
est degree of flexibility for the alignment of bis(urea) motifs. 
The situation of C2 lies in between those two extremes.  
 
Supramolecular Gel Phase Crystallization of Cisplatin. Gel 
phase crystallization commonly involves dissolving the 
LMWG and the substrate in a common solvent under soni-
cation and/or heating to give a homogeneous sol that is then 
allowed to cool, resulting in rapid gelation followed by crys-
tallization on a slower time scale.
13
 However, the insolubility 
of cisplatin in most organic solvents except DMF means that 
this strategy is not viable. As a result we adopted a method 
involving a biphasic gel-sol system, in which a cisplatin solu-
tion in DMF was allowed to diffuse into a contiguous gel 
based on targeted gelators C1–3 prepared in another suitable 
solvent (Figure 3). The advantages of this process are two-
fold: firstly, simultaneous heating of both the components is 
not required, therefore minimizing the possibility of chemical 
reaction between two structurally similar compounds; second-
ly, it eliminates the necessity of having a common solvent, 
therefore adding more versatility in terms of solvent selection.
Pt-Cl 
stretching 
 C1  C2  C3 
 322 (sh), 
325.7 
 324.5, 
329.5 
 324.5, 
329.5 
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In a typical procedure, a cisplatin solution in DMF (1.5% w/v) 
was added slowly on the top of a pre-formed gel (2% w/v) 
prepared in another organic solvent. Gels of C1 and C3 in o-
xylene (p- and m-xylene gave similar results) produced yellow 
plate-like crystals. A control experiment in pure DMF did not 
result in crystal formation under the same conditions. Replac-
ing the targeted gel with o-xylene gels of a generic LMWG G 
bearing no structural similarity to cisplatin (Supporting Infor-
mation Figure S25)
24b
 or by replacing the gel with pure o-
xylene solvent, also generated similar plate-like crystals. Sin-
gle crystal X-ray diffraction confirmed the crystals as the 
known triclinic DMF solvate of cisplatin.
20b
 Crystallization 
results are summarized in Table 3. The most interesting find-
ing was the temperature dependence of the crystal morphology 
observed in the presence of C3. While low temperature crys-
tallization in the presence of the C3 gel and in the control ex-
periments produced yellow plate-like crystals with irregular 
shapes, room temperature (20 
o
C) crystallization in the C3 gel 
produced a substantial fraction of yellow hexagonal plate-like 
crystals in addition to irregular plates. This represents a novel 
morphology for the cisplatin DMF solvate and could be gener-
ated only in the presence of C3 gels in xylenes near to room 
temperature. Habit modification may indicate selective ad-
sorption of the gelator on the fastest growing face of the crys-
tals.
30
 Interestingly, none of the gels prepared from C2 (in all 
gel-forming alcohols) gave cisplatin crystals using the same 
layering approach, presumably reflecting the more polar sol-
vent. Also, gels prepared from C1 and C3 in solvents other 
than xylenes did not result cisplatin crystals. 
 Despite its facile formation, the DMF solvate is unstable 
and rapidly loses DMF upon exposure to atmosphere. This 
observation prompted us to find an alternative solvent to re-
place the DMF, despite the lack of other known solvate forms. 
Cisplatin precipitates immediately from N,N-
diethylformamide (DEF) whereas it is moderately soluble in 
N,N-dimethylacetamide (DMA). Interestingly, the same bi-
layer gel-sol technique using DMA solvent yielded high quali-
ty yellow rectangular plate-like single crystals from gels of C3 
in o-, m- and p-xylene. In contrast, control experiments per-
formed in the presence of o-xylene gels of either C1 or G pro-
duced only a mass of small microcrystals (Figure 4) suggest-
ing an effect of the gel on controlling crystal nucleation fre-
quency. The crystals obtained from the C3 gel were character-
ized by single crystal X-ray crystallography and proved to be a 
new solvate form of cisplatin incorporating one DMA mole-
cule per two cisplatin molecules (Figure 5).
31
 This material is 
only the second known solvate form of cisplatin. The material 
crystallizes in space group Pī and has a related channel struc-
ture to the triclinic DMF solvate in the same space group. Full 
crystallographic parameters are given in Tables S2-S9 in the 
Supporting Information. However, unlike the related triclinic 
DMF solvate
20b
 which has a 1:1 solvent to cisplatin ratio the 
asymmetric unit has two cisplatin molecules to one DMA 
(Figure 5a). The solvent molecule is disordered with each at-
om over two positions with occupancy of 0.75 and 0.25 re-
spectively.  The packing arrangement in the crystal is shown 
in Figure 5b. The two unique cisplatin molecules both have a 
square planar geometry and are linked through N-H∙∙∙Cl hy-
drogen bonding (N∙∙∙Cl 3.424(5), 3.443(6) Å; N-Ĥ∙∙∙Cl 171–
175
o
) (Supporting Information Figure S26 and Table S7). The 
carbonyl group of the DMA molecule interacts with the am-
mine ligands of the cisplatin via N-H∙∙∙O hydrogen bonding 
(N∙∙∙O 2.889(13) Å, N-Ĥ∙∙∙O 159
o
). In addition, close Pt∙∙∙Pt 
interactions of 3.205(5) and 3.316(8) Å are also present as 
observed in other platinum(II) complexes.
17, 20, 32
  
 The crystalline material from all DMA crystallizations 
was analyzed by X-ray powder diffraction (XRPD) to assess 
bulk solid form. The data indicate that the samples are a mix-
ture of varying amounts of the new DMA solvate form and 
solvent-free cisplatin, identified by fitting to the calculated 
patterns derived from single crystal data (see supplementary 
information Figures S27–32).
19,31
 There is also evidence for 
small amounts of an additional unidentified phase. Gels of 
generic gelator G yielded crystals that are predominantly cis-
platin DMA solvate with some alpha cisplatin. Gels of C1 and 
C3 gave a mixture of the DMA solvate and both alpha and 
beta cisplatin. The presence of alpha and beta cisplatin may 
arise from desolvation of initially formed solvate during the 
preparation of the sample for XRPD, although concomitant 
formation of solvate and pure cisplatin forms cannot be ruled 
out. The data establish that all of the supramolecular gels G, 
C1 and C3 are capable of producing the new DMA hemisolv-
ate form of cisplatin. However, the drug-mimic LMWG C3 
produced high quality single crystals suitable for single crystal 
X-ray diffraction.  
(a) (b) (c) 
Figure 1. SEM micrographs of the xerogel systems (1.5% w/v): (a) C1 in toluene, (b) C2 in 1-propanol and (c) C3 in toluene. 
Inset: photographs of the gel samples. 
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Initial control experiments based on diffusing a DMA solution 
of cisplatin into o-xylene did not result in formation of the 
DMA solvate phase. However, later control experiments did 
result in formation of mixtures of the solvate and amorphous 
material. The size of the DMA solvate crystals from the con-
trol system was improved and the amount of amorphous mate-
rial decreased by undertaking the crystallization at low tem-
perature (4 
o
C). Since the new solvate was formed initially in 
the gels and appeared only in control experiments without the 
gels some months afterwards it is possible that seeding from 
the gel-grown sample is a factor in the formation of the DMA 
solvate. 
 The thermal stability of the new DMA hemisolvate was 
analyzed by thermogravimetric analysis. A wet sample ob-
tained from gels of G was used in order to avoid any possible 
interference which might arise from C3 having similar func-
tional groups as those of cisplatin. The thermogram shows that 
loss of surface DMA is complete by 63 
o
C while included 
DMA is lost shortly afterwards in a continuous process con-
sistent with the channel nature of the solvate (Figure 6). Elim-
ination of two ammonia ligands takes place in stepwise man-
ner, followed by loss of chlorine. 
 XRPD patterns of the xerogel samples of C1 and C3 
prepared from o-xylene give distinct maxima in the low angle 
region (Figure 7) with a particularly sharp feature in the case 
of C3. The d-spacing matches closely with the approximated 
‘ordered length’ up to the first 6 carbons after the urea motif of 
the extended C3 gelator suggesting partial dodecyl chain dis-
order in an extended conformation in the gel state with stacked 
“PtCl2” units. In contrast the d-spacing obtained from the 
XRPD data of C1 proved to be shorter than the calculated 
length of the molecular axis for an extended conformation 
based on an ordered length of six methylene units. Direct at-
tachment of urea with the coordinating pyridyl group may 
introduce a steric barrier preventing an extended conformation 
in the gel. This difference in the conformational freedom may 
be linked to the ability of C3 to produce high quality crystal 
samples. 
 
CONCLUSIONS 
A series of platinum bearing LMWGs C1, C2 and C3, mim-
icking the structure of cisplatin has been prepared. The C3 gel 
with its greater separation of urea and ligating groups proved 
to the most effective gelator. The cisplatin targeted gels were 
incorporated into a biphasic gel-sol system for crystallization 
of the highly insoluble cisplatin. An interesting crystal habit 
modification of the cisplatin triclinic DMF solvate of cisplatin 
in the presence of only the C3 gel was observed. A new DMA 
hemisolvate of cisplatin is produced by both designer and non-
specific gels, however the highest quality single crystals were 
obtained from the targeted C3 gel under the conditions em-
ployed. We suggest that the structural and geometrical resem-
blance between this gelator and cisplatin together with the 
relatively ordered assembly in this gel enhance the influence 
of the C3 gels on cisplatin crystallization. The mode of inter-
action between the gelator and substrate may involve a combi-
nation of Pt-Pt stacking and ammine-chloride hydrogen bond-
ing interactions. To the best of our knowledge, this is the first 
evidence for the use of a drug-mimic supramolecular LMWG 
system in influencing the outcome of a drug crystallization 
process. The concepts of designer LMWG as part of a biphasic 
gel-sol diffusion arrangement offer an intriguing new potential 
tool in pharmaceutical solid form screening. 
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Figure 2. Determination of the linear regime: Measurement of storage and loss moduli as a function of applied stress at a constant 
angular frequency of 1 Hz, performed at 20 oC for different gel systems (2.5% w/v): (a) C1 in toluene, (b) C2 in 1-propanol and (c) 
C3 in toluene. 
(a) (b) 
Figure 3. (a) Photo showing the yellow cisplatin crystals 
grown at the interface of the gel-sol bilayer system consisting 
of a o–xylene gel of C3 (2% w/v) at the bottom layer and a 
solution of cisplatin in DMF at the top layer; (b) Optical 
microscope image (90 times magnification) of the cisplatin 
crystals grown at the gel-sol interface, at room temperature. 
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Table 3. Crystallization of cisplatin studied in gel-sol bilayer systems, where cisplatin dissolved in DMF constitutes the top layer 
and various systems as described below form the bottom layer, including a control experiment without a bottom layer. 
  o–xylene gel of C3  o–xylene gel of C1  o-xylene 
gel of G 
 o–xylene  None 
Temperature 
(oC) 
 10  20  10  20  20   20   
Crystal form  
DMF 
solvate 
 
DMF 
solvate 
 
DMF 
solvate 
 
DMF 
solvate 
 
DMF 
solvate 
 
DMF 
solvate 
 
No  
crystal 
Morphologya  
 
 
 
 
 
 
 
 
 
 
 
  
a
 Photographs of the crystals as mounted for single crystal X-ray study 
 
 
 
EXPERIMENTAL SECTION 
Materials. Cisplatin was purchased from TCI and was estab-
lished to be beta-cisplatin by XRPD (see supplementary in-
formation, Figure S29). Ligands L1, L2 and L3 were prepared 
from the reaction of pyridyl amines with dodecyl isocyanate. 
In a typical procedure, the amine (1 equivalent) was dissolved 
in dry dichloromethane. The solution was cooled to 0 
o
C and 
dodecyl isocyanate (1.2 equivalents) dissolved in dichloro-
methane was added to the reaction mixture drop wise using an 
addition funnel, under the nitrogen atmosphere. The reaction 
mixture was allowed to warm to room temperature followed 
by reflux overnight. Products were collected and purified as 
described below. 
1-dodecyl-3-(pyridin-3-yl)urea (L1). 3-aminopyridine (0.5 g, 
5.31 mmol) reacted with dodecyl isocyanate (1.35 g, 6.40 
mmol).The solvent was removed in vacuo and the crude prod-
uct was recrystallised from ethanol at 0 
o
C to give a white 
powder (1.22 g, yield 75%). 
1
H NMR (400 MHz, DMF-d7): δ 8.90 (1H, s, Ar-NH), 8.80 
(1H, s, ArH), 8.29 (1H, d, J = 4.6 Hz, ArH), 8.17 (1H, d, J = 
2.6 Hz, ArH), 7.41 (1H, dd, J = 4.7, 4.3 Hz, ArH), 6.52 (1H, t, 
J = 5.6, -NHC12H25), 3.35 (2H, q, J = 6.8 Hz, -CH2C11H23) , 
1.67 (2H, quin, J = 7.1 Hz, -CH2C10H21), 1.43 (18H, m, -
CH2C9H18CH3), 1.03 (3H, t, J = 6.8 Hz, -CH3); 
13
C{
1
H} NMR 
(151 MHz, DMF-d7): δ 155.71, 142.36, 140.01, 138.06, 
124.50, 123.55, 39.73, 31.95, 30.35, 29.72, 29.69, 29.45, 
26.97, 22.66, 13.83; FT-IR (νmax/cm
-1
): 3339, 3041, 2955, 
2917, 2850, 1673, 1651, 1558; Anal. calcd for C18H31N3O: C 
70.78, H 10.23, N 13.76, found C 70.72, H 10.21, N 13.65; 
MS (ESI): m/z calcd 306.2, found 306.2 [M+H]
+
. 
1-dodecyl-3-((pyridin-3-yl)methyl)urea (L2). 3-picolylamine 
(0.5 g, 4.62 mmol) reacated with dodecyl isocyanate (1.17 g, 
5.55 mmol). The reaction mixture was allowed to cool at room 
temperature and the precipitate was collected by filtration to 
give a white powder (1.25 g, yield 85%).  
1
H NMR (400 MHz, DMF-d7): δ 8.73 (1H, s, ArH), 8.63 (1H, 
d, J = 4.8 Hz,  ArH), 7.89 (1H, d, J = 7.8 Hz, ArH), 7.52 (1H, 
dd, J = 4.8 Hz, ArH), 6.65 (1H, t, J = 5.8 Hz, ArCH2NH), 6.29 
(1H, t, J = 5.6 Hz, -NHC12H25), 4.54 (2H, d, J = 6.1 Hz, 
ArCH2-), 3.31 (2H, q, J = 6.8 Hz, -CH2C11H23), 1.63 (2H, 
quin, J = 6.7 Hz, -CH2C10H21), 1.46 (18H, m, -CH2C9H18CH3), 
1.06 (3H, t, J = 6.9 Hz, -CH3); 
13
C{
1
H} NMR (151 MHz, 
DMF-d7): δ 158.65, 149.22, 148.20, 137.16, 135.03, 123.50, 
41.20, 40.00, 31.96, 30.67, 29.73, 29.50, 27.01, 22.67, 13.84; 
FT-IR (νmax/cm
-1
): 3346, 3313, 3037, 2960, 2921, 2849, 1615, 
1569; Anal. calcd. for C19H33N3O: C 71.43, H 10.41, N 13.15, 
found C 71.35, H 10.37, N 13.09; MS (ESI): m/z calcd. 320.2, 
found 320.1 [M+H]
+
. 
1-dodecyl-3-(2-(pyridin-3-yl)ethyl)urea (L3). 3-(2-
aminoethyl)pyridine (0.5 g, 4.1 mmol) reacted with dodecyl 
isocyanate (1.04 g, 4.92 mmol). The solvent was removed in 
vacuo and the crude product was purified by column chroma-
tography [silica gel, CHCl3/ MeOH = 15:1 (v/v)] to give yel-
lowish white powder (1.06 g, yield 78%). 
1
H NMR (400 MHz, DMF-d7): δ 8.65 (1H, s, ArH), 8.63 (1H, 
d, J = 4.9 Hz, ArH), 7.83 (1H, d, J = 7.8 Hz, ArH), 7.52 (1H, 
dd, J = 4.8 Hz, ArH), 6.12 (2H, br, -CH2NHCONHCH2-), 3.56 
(2H, q, J = 6.7 Hz, ArCH2CH2NH-), 3.26 (2H, q, J = 6.8 Hz, -
NHCH2C11H23), 2.96 (2H, t, J = 7.0 Hz, ArCH2CH2-), 1.60 
(2H, quin, J = 6.6 Hz, -CH2C10H21), 1.46 (18H, m, -
CH2C9H18CH3), 1.06 (3H, t, J = 6.8 Hz, -CH3); 
13
C{
1
H} NMR 
(151 MHz, DMF-d7) δ 158.56, 150.46, 147.70, 136.33, 
135.78, 123.57, 41.14, 39.86, 33.83, 31.96, 30.70, 29.74, 
29.70, 29.50, 27.02, 22.67, 13.84; FT-IR (νmax/cm
-1
): 3338, 
3313, 3033, 2955, 2922, 2849, 1615, 1571; Anal. calcd. for 
C20H35N3O: C 72.03, H 10.58, N 12.60, found C 72.05, H 
10.56, N 12.55; MS (ESI): m/z calcd. 334.2, found 334.1 
[M+H]
+
. 
Synthesis of C1, C2, C3. A hot aqueous solution of potassium 
tetrachloroplatinate was added to the hot ligand solution in 2-
propanol (2-propanol: water = 2:1, v/v) and then the reaction 
mixture was refluxed at 75
 o
C for 3 days then allowed to cool 
at room temperature. The resulting precipitate was filtered and 
washed with hot and cold 2-propanol, and hot and cold dis-
tilled water. The crude product was purified by column chro-
matography [silica gel, CHCl3: MeOH = 20:1 (v/v)] to give a 
beige powder. 
Dichloro-bis(1-dodecyl-3-(pyridin-3-yl)urea)platinum (II) 
(C1). Ligand L1 (0.23 g, 0.76 mmol) reacted with potassium 
tetrachloroplatinate (0.16 g, 0.38 mmol) to give C1 (0.15 g, 
yield 45%) 
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1
H NMR (400 MHz, DMF-d7): δ 9.37 (0.4 H, s, ArH), 9.29 
(2H, s, ArNH-), 9.16 (1.6 H, s, ArH), 8.57 (0.4 H, d, J = 
5.3Hz, ArH), 8.46 (1.6 H, d, J = 5.3 ArH), 8.31 (1.6 H, d, J = 
8.4 Hz, ArH), 8.21 (0.5 H, br ArH), 7.53 (2H, dd, J = 5.7 Hz, 
ArH), 6.70 (2H, t, J = 5.5 Hz, -NHC12H25), 3.33 (4H, q, J = 6.2 
Hz, -CH2C11H23), 1.66 (4H, quin, J = 6.7 Hz, -CH2C10H21), 
1.43 (36H, m, -CH2C9H18CH3), 1.03 (6H, t, J = 6.8 Hz, -CH3); 
13
C{
1
H} NMR (151 MHz, DMF-d7) δ 155.09, 146.10, 145.19, 
143.61, 142.54, 140.13, 139.31, 126.96, 126.18, 125.25, 
39.81, 31.94, 30.17, 29.72, 29.40, 29.38, 26.95, 22.65, 13.84; 
FT-IR (νmax/cm
-1
): 3359, 3300, 2953, 2920, 2848, 1638, 1554; 
Anal. calcd. for C36H62Cl2N6O2Pt: C 49.31, H 7.13, N 9.58, 
found C 49.11, H 7.08, N 9.54; MS (MALDI): m/z calcd. 
899.0, found 899.4 [M+Na]
+
.  
Dichloro-bis(1-dodecyl-3-((pyridin-3-yl)methyl)urea)platinum 
(II) (C2). Ligand L2 (0.46 g, 1.44 mmol) reacted with potassi-
um tetrachloroplatinate (0.3g, 0.72 mmol) to give C2 (0.42 g, 
yield 64%). 
1
H NMR (400 MHz, DMF-d7): δ 9.01(2H, s, 
ArH), 8.93 (2H, d, J = 5.8 Hz, ArH), 8.14 (2H, d, J = 7.8 Hz, 
ArH), 7.70 (2H, dd, J = 5.8 Hz, ArH), 6.82 (2H, t, J = 6.0 Hz, 
ArCH2NH-), 6.43 (2H, t, J = 5.7 Hz, -NHC12H25), 4.60 (4H, d, 
J = 6.0 Hz, ArCH2-), 3.31 (4H, q, J = 6.8 Hz, -CH2C11H23), 
1.65 (4H, quin, J = 6.8 Hz, -CH2C10H21), 1.45 (36H, m, -
CH2C9H18CH3), 1.06 (6H, t, J = 7.0 Hz, -CH3); 
13
C{
1
H} NMR 
(151 MHz, DMF-d7) δ 158.58, 152.59, 151.99, 139.86, 
(a) (b) (c) 
Figure 4. Optical microscope images (90 times magnification) of cisplatin crystals grown in the presence of different gel systems 
prepared in o-xylene (2% w/v): (a) C3 (b) C1 and (c) G. 
(a) 
(b) 
Figure 5. (a) A View of the asymmetric unit of cisplatin 
DMA solvate showing the atom numbering scheme and (b) 
packing diagram of the cisplatin DMA solvate viewed along 
the c axis. 
Figure 6. TGA-MS thermograms of cisplatin sample collect-
ed from G (a small but constant time lag is involved in the 
mass analysis). The region on the left of the dotted line ap-
proximates the elimination of ‘free solvent’ from the wet 
system. The black arrows indicate the points of elimination of 
the included solvent and ligands. The mass calculation of the 
different components was based on the formula 
2PtCl2(NH3)2.C4H9NO staring from the conclusion of surface 
solvent loss at 67.5 wt%. The elimination of Cl was assigned 
based on the residual mass of Pt. 
100 200 300 400 500
30
40
50
60
70
80
90
100
 TGA
 MS-C
4
H
9
NO
 MS-NH3
 
 
Temperature (
o
C)
W
e
ig
h
t 
(%
)
-C
4
H
9
NO (8.5%)
-NH
3
 (3.3%)
-Cl (14%)
P
re
s
s
u
re
 (
a
.u
.)
-NH
3
 (3.3%)
8 
 
138.34, 125.36, 40.77, 40.10, 31.97, 29.75, 27.06, 22.68, 
13.85; FT-IR (νmax/cm
-1
): 3348, 3304, 3045, 2953, 2921, 2848, 
1624, 1577; Anal. calcd. for C38H66Cl2N6O2Pt: C 50.43, H 
7.35, N 9.29, found C 50.23, H 7.31, N 9.27; MS (MALDI): 
m/z calcd. 927.0, found 927.4 [M+Na]
+
. 
Dichloro-bis(1-dodecyl-3-(2-(pyridin-3-yl)ethyl)urea)platinum 
(II) (C3). Ligand L3 (0.32 g, 0.96 mmol) reacted with potassi-
um tetrachloroplatinate (0.2 g, 0.48 mmol) to give C3 (0.18 g, 
yield 40%). 
1
H NMR (400 MHz, DMF-d7): δ 8.94 (4H, m, 
ArH), 8.11 (2H, d, J = 7.8 ArH), 7.70 (2H, dd, J = 5.8 ArH), 
6.24 (2H, t, J = 5.7 Hz, ArCH2CH2NH-), 6.13 (2H, t, J = 5.6 
Hz, -NHC12H25), 3.59 (4H, q, J = 6.8 Hz, ArCH2CH2-), 3.28 
(4H, q, J = 6.6 Hz, -NHCH2C11H23), 3.07 (4H, t, J = 7.0 Hz, 
ArCH2-), 1.63 (4H, quin, J = 6.6 Hz, -CH2C10H21), 1.46 (36H, 
m, -CH2C9H18CH3), 1.06 (6H, t, J = 6.7 Hz, -CH3); 
13
C{
1
H} 
NMR (151 MHz, DMF-d7): δ 158.56, 153.68, 151.57, 139.74, 
138.23, 125.39, 40.74, 39.93, 33.50, 31.96, 30.69, 29.74, 
27.06, 22.67, 13.84; FT-IR (νmax/cm
-1
): 3340, 3315, 3037, 
2956, 2922, 2849, 1614, 1574; Anal. calcd. for 
C40H70Cl2N6O2Pt: C 51.49, H 7.56, N 9.01, Found C 51.37, H 
7.55, N 8.98; MS (MALDI): m/z calcd. 933.0, found 933.4 
[M+H]
+
. 
Synthesis of G. The synthesis of G was carried out using a 
procedure described previously.
24b 1
H NMR (400 MHz, 
DMSO-d6) δ 7.33 (1H, s, ArH), 7.14 (3H, m, ArH), 6.12 (2H, 
s, ArC(CH3)2 NH), 5.82 (2H, t, J = 5.8 Hz, - NHCH2-), 3.75 
(12H, q, J = 6.9 Hz, -OCH2-), 2.90 (4H, q, J = 5.9 Hz, -
NHCH2-), 1.51 (12H, s, Ar-C(CH3)2-), 1.38 (4H, quin, J = 7.5 
Hz, -CH2CH2CH2-), 1.15 (18H, t,  J = 6.9 Hz, -CH2CH3), 0.51 
(4H, t, J = 8.1 Hz, -CH2Si); Anal. calcd. for C32H62N4O8Si2: C 
55.94, H 9.10, N 8.15, Found C 56.01, H 9.01, N 8.11; MS 
(ESI): m/z calcd. 709.4, found 709 [M+Na]
+. 
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